Helen Torley Sells 20,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Key Points

• CEO Helen Torley of Halozyme Therapeutics sold 20,000 shares at $63.51 each, totaling $1,270,200, reducing her ownership by 2.65%.
• In its last earnings report, Halozyme Therapeutics posted $1.54 earnings per share, surpassing expectations and reflecting a 40.8% increase in quarterly revenue year-over-year.
• Analysts have mixed ratings on Halozyme, with most recommending a "Hold" while the average target price stands at $66.56.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at $46,598,493.69. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Helen Torley also recently made the following trade(s):

• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00.
• On Tuesday, June 24th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $53.73, for a total value of $1,074,600.00.
• On Friday, June 20th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $52.96, for a total transaction of $1,059,200.00.

Halozyme Therapeutics Trading Up 2.3%

Halozyme Therapeutics stock traded up $1.52 during mid-day trading on Monday, hitting $68.79. 528,126 shares of the company's stock were exchanged, compared to its average volume of 1,948,239. Halozyme Therapeutics, Inc. has a fifty-two week low of $42.01 and a fifty-two week high of $70.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The firm has a market capitalization of $8.05 billion, a P/E ratio of 15.76, a PEG ratio of 0.37 and a beta of 1.17. The company's 50 day simple moving average is $57.06 and its 200-day simple moving average is $58.28.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%. Halozyme Therapeutics's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.91 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HALO shares. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. JMP Securities raised their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. Leerink Partnrs cut Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, Morgan Stanley increased their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research note on Monday. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $67.11.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at $21,838,000. Capital Fund Management S.A. acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $1,118,000. CreativeOne Wealth LLC raised its holdings in Halozyme Therapeutics by 1.6% during the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 294 shares in the last quarter. XTX Topco Ltd acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $691,000. Finally, Marshall Wace LLP bought a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $212,000. 97.79% of the stock is owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.